Related Experiment Video

Updated: Aug 23, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Cyclosporine increases endothelin-1 plasma levels in renal transplant recipients

R L Cauduro1, C Costa, F Lhulier

  • 1Renal Division, Hospital de Clínicas de Porto Alegre and Post-Graduation in Medical Sciences, Nephrology Program, Rio Grande do Sul Federal University, Porto Alegre, RS, Brazil.

Transplantation Proceedings
|June 15, 2004
PubMed

Insights

Cyclosporine therapy may increase endothelin-1 (ET-1) levels, a factor linked to hypertension in kidney transplant patients. This study found higher ET-1 in patients taking cyclosporine, suggesting its role in post-transplant hypertension.

Area of Science:

  • Nephrology
  • Cardiovascular Research
  • Pharmacology

Background:

  • Endothelin-1 (ET-1) is implicated in hypertension development.
  • Cyclosporine is a common immunosuppressant in renal transplantation.
  • A potential link exists between cyclosporine, ET-1, and hypertension post-transplant.

Purpose of the Study:

  • To investigate the association between cyclosporine administration and ET-1 levels.
  • To explore the role of ET-1 in hypertension among renal transplant recipients using cyclosporine.

Main Methods:

  • Observational study design.
  • Comparison of ET-1 levels in 33 cyclosporine-treated renal transplant recipients versus 10 controls.
  • Measurement of ET-1 levels 3 hours post-cyclosporine administration.

Main Results:

  • Significantly higher ET-1 levels were observed in cyclosporine-treated patients (1.81 ± 0.99 pg/mL) compared to controls (1.17 ± 0.46 pg/mL).
  • The difference in ET-1 levels was statistically significant (P < .04).

Conclusions:

  • Elevated ET-1 levels following cyclosporine administration suggest a potential mechanism for hypertension in renal transplant recipients.
  • ET-1 may play a role in the pathogenesis of post-transplant hypertension associated with cyclosporine therapy.

More Related Videos

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...